Skip to content

Twist Bioscience

US · TWST #1258 by market cap Listed 2018
103.32 -8.30 -7.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 16.45, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail
  • Next-Generation Sequencing (NGS) applications is the largest reported line at 52.21% of revenue, across 2 reported segments.
  • DNA synthesis and protein solutions follows at 47.79%, so the top line still matters most but isn’t the whole story.

Revenue annual, last 8 years

Latest year +22.00% YoY

Margins

Gross margin
52.41%
Operating margin
-28.79%
Net margin
-28.34%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 54.39M90.10M132.33M203.57M245.11M312.97M376.57M459.43M
Gross profit 6.96M28.69M51.71M84.24M89.73M133.35M191.00M240.80M
Selling & admin expenses 80.13M103.27M135.90M212.95M189.74M218.40M246.98M301.22M
Research & development 35.68M43.01M69.07M120.31M106.89M90.85M80.29M71.84M
Operating profit -108.85M-117.58M-153.26M-249.02M-206.90M-175.90M-136.26M-132.25M
Pretax profit -107.38M-139.55M-154.03M-228.27M-203.47M-208.17M-76.95M-129.80M
Tax 292.00K382.00K-1.93M-10.41M1.15M560.00K719.00K406.00K
Net profit -107.67M-139.93M-152.10M-217.86M-204.62M-208.73M-77.67M-130.20M
Basic EPS -4-4-3-4-4-4-1-2
Diluted EPS -3.92-3.57-3.15-4.04-3.60-3.60-1.30-2.08

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 160.14M334.87M546.50M596.48M424.26M346.78M332.97M737.22M
Cash & ST investments 138.11M290.00M477.86M504.97M336.41M276.40M232.43M581.91M
Inventory 7.33M12.29M31.80M39.31M32.06M24.08M28.31M46.41M
Total assets 186.99M398.88M702.10M961.38M776.40M614.32M641.86M1.12B
Total current liabilities 30.35M36.03M63.05M90.66M73.32M71.01M91.41M125.81M
Short-term debt 3.33M9.74M9.77M13.64M14.90M14.81M13.82M8.45M
Long-term debt 4.40M1.40M------------
Total liabilities 34,912,000.0062,620,000.00121,276,000.00171,993,000.00152,971,000.00141,634,000.00168,903,000.00233,792,000.00
Total equity 152.08M336.26M580.82M789.39M623.43M472.69M472.96M888.02M
Retained earnings -318.52M-458.46M-610.55M-828.42M-1.03B-1.24B-1.32B-1.45B

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow -87.94M-142.26M-112.24M-124.39M-142.47M-64.09M-47.63M-41.43M
Depreciation & amortization 6.11M6.68M9.75M16.51M29.31M31.43M24.85M26.48M
Free cash flow -102.69M-152.12M-139.31M-226.24M-170.25M-69.17M-75.63M-95.96M
Dividends paid ----------------
Stock buybacks / issuance 156.21M293.14M313.01M262.07M-4.41M-3.98M-16.00K424.79M
Ending cash balance 47.40M94.25M467.36M380.26M289.28M229.13M185.43M537.61M

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % ---57.31-33.17-31.80-28.97-38.08-16.43-19.13
ROA % -71.12-47.77-27.63-26.19-23.55-30.02-12.37-14.76
ROIC % ---52.80-29.95-28.89-26.88-35.14-15.57-17.69
5-year avg ROE % -----------37.87-29.69-26.88
EBIT margin % -195.06-154.01-116.12-112.10-83.01-66.50-36.18-28.79
FCF / sales % ----------------
Current ratio 5.289.298.676.585.794.883.645.86
Quick ratio 4.958.788.036.015.194.383.215.37
Debt / assets 4.149.028.969.8712.1213.8411.778.47
LT debt / equity 2.897.809.1510.3012.7014.8613.069.75
Interest coverage -81.98-176.32-418.69-2,852.43-40,692.20-7,177.14----
Revenue CAGR (3Y) % 188.32103.0273.3055.2739.6033.2322.7623.30
Net income CAGR (3Y) % ----------------
FCF CAGR (3Y) % ----------------

Revenue breakdown most recent period

Business

Next-Generation Sequencing (NGS) applications52.21%
DNA synthesis and protein solutions47.79%

Quote time 2026-11-20 19:52:04 · For reference only, not investment advice and not tailored to your situation.

Twist Bioscience discussion 0 comments

Add a comment